NeuroOne Medical Technologies Corporation - Common Stock (NQ:NMTC)

NeuroOne Featured in New York Post on OneRF® Patient’s Remarkable Journey to Overcome Debilitating Facial Pain

October 27, 2026

NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program

Performance

52-Week Range 84.7% below 52-week high

0.9348

0.7752W Low 6.1252W High

1 Week 10.1% below 1-week high

0.801W Low 1.041W High

NeuroOne Medical Technologies Corporation - Common Stock (NMTC) traded between $0.77 and $6.12 over the past 52 weeks and last traded at $0.93, 84.7% below its 52-week high. Over the past week it ranged between $0.80 and $1.04.

Past 12 Months

+10.0%

-16.2%

-45.0%

-79.2%

-81.7%

-79.6%

1W +$0.08

1M -$0.18

3M -$0.77

6M -$3.56

YTD -$4.18

1Y -$3.65

NMTC was -79.6% over the past year, -79.2% over six months, -81.7% year to date, +10.0% in the last week.

12 Months vs Market

NMTC

-79.6%

DIA

+9.7%

SPY

+10.1%

QQQ

+7.8%

IWM

+13.7%

Over the past 12 months NMTC returned -79.6% versus DIA (Dow) +9.7%, SPY (S&P 500) +10.1%, QQQ (Nasdaq 100) +7.8% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.04× 3-mo avg

Today 12,662 3-mo avg 342.2K

37.6K

142.6K

342.2K

194.3K

YTD

135.2K

119.1K

NMTC most recently traded 12,662 shares against a 3-month average daily volume of 342.2K.

More News

October 22, 2026

NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology

October 08, 2026

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

October 05, 2026

NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

NeuroOne (NMTC) Q2 2026 Earnings Transcript ↗

June 01, 2026

Via The Motley Fool

September 17, 2026

BioMedNewsBreaks — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) Completes Three Large-Animal Procedures Using StereoCED(TM) Platform

August 27, 2026

Via Investor Brand Network

NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED(TM) Platform

August 27, 2026

NeuroOne(R) Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%

NeuroOne (NMTC) Q3 2026 Earnings Call Transcript ↗

August 20, 2026

Via The Motley Fool

August 13, 2026

NeuroOne(R) Achieves Major Milestone With ISO 13485 Certification

August 11, 2026

NeuroOne(R) to Report Third Quarter Fiscal Year 2026 Financial Results on Thursday, August 13, 2026, at 8:30 a.m. Eastern Time

August 03, 2026

NeuroOne Releases CNS Drug Delivery White Paper Ahead of Planned Fiscal Year-End Availability of the StereoCED(TM) Platform

July 30, 2026

NeuroOne(R) Highlights Potential Paradigm Shift for Patients Treated With the OneRF(R) Brain Ablation System Based on Reports by Physicians

July 28, 2026

NeuroOne(R) Expands Drug Delivery Program Through Collaboration on Pediatric Brain Cancer Clinical Trial

July 16, 2026

NeuroOne(R) Added to Russell Microcap(R) Index

June 29, 2026

NeuroOne(R) Added to Russell Microcap(R) Index

June 29, 2026

NeuroOne(R) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 25, 2026

NeuroOne(R) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 25, 2026

NeuroOne(R) Announces Preliminary Inclusion in Russell Microcap(R) Index

June 16, 2026

NeuroOne(R) Announces Preliminary Inclusion in Russell Microcap(R) Index

June 16, 2026

NeuroOne(R) to Present at the Planet MicroCap Las Vegas 2026 Conference Wednesday, June 17, 2026 at 12:00 p.m. Pacific Time

June 08, 2026

NeuroOne(R) to Present at the Planet MicroCap Las Vegas 2026 Conference Wednesday, June 17, 2026 at 12:00 p.m. Pacific Time

June 08, 2026

NeuroOne(R) to Present at the 2026 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting on May 31, 2026

May 28, 2026